Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Leukemia. 2012 Jun;26(6):1293-300. doi: 10.1038/leu.2011.357. Epub 2011 Dec 13.
Impaired cell death program has been noted as one of the hallmarks of chronic lymphocytic leukemia (CLL) and contributes to its accumulation of malignant monoclonal B cells as well as to chemotherapy resistance. A cell can die through the apoptosis or necrosis pathway. Recent investigations suggest that in apoptotic-deficient conditions, such as most types of cancer, a process of programmed necrosis, called necroptosis, prevails. However, the detailed molecular mechanisms underlying this alternative cell death pathway are still not fully understood. Here we demonstrate that CLL cells failed to undergo necroptosis upon stimulation of TNFα combined with pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD). Two core components of necroptotic machine, RIP3 and deubiquitinase cylindromatosis (CYLD), are markedly downregulated in CLL. Moreover, we identified lymphoid enhancer-binding factor 1 (LEF1), a downstream effector of the Wnt/β-catenin pathway, as a transcription repressor of CYLD in CLL. Knocking down LEF1 sensitizes CLL cells to TNFα/zVAD-induced necroptosis. The present investigation provides the first evidence that CLL cells have defects not only in apoptotic program but also in necroptotic signaling. Targeting the key regulators of necroptotic machine, such as LEF1, to restore this pathway may represent a novel approach for CLL treatment.
细胞死亡程序受损已被认为是慢性淋巴细胞白血病 (CLL) 的特征之一,这不仅导致恶性单克隆 B 细胞的积累,还导致对化疗的耐药性。细胞可以通过凋亡或坏死途径死亡。最近的研究表明,在凋亡缺陷的情况下,如大多数类型的癌症,一种称为坏死性凋亡的程序性坏死过程占主导地位。然而,这种替代细胞死亡途径的详细分子机制尚不完全清楚。在这里,我们证明 CLL 细胞在 TNFα 联合泛半胱天冬酶抑制剂苯甲氧基羰基-Val-Ala-Asp-氟甲基酮 (zVAD) 刺激下未能发生坏死性凋亡。坏死性凋亡机器的两个核心组件 RIP3 和去泛素化酶环指蛋白肿瘤抑制因子 (CYLD) 在 CLL 中明显下调。此外,我们确定淋巴增强结合因子 1 (LEF1),Wnt/β-连环蛋白通路的下游效应物,是 CLL 中 CYLD 的转录抑制剂。敲低 LEF1 可使 CLL 细胞对 TNFα/zVAD 诱导的坏死性凋亡敏感。本研究首次证明 CLL 细胞不仅在凋亡程序中存在缺陷,而且在坏死性凋亡信号中也存在缺陷。靶向坏死性凋亡机器的关键调节因子,如 LEF1,以恢复该途径可能代表 CLL 治疗的一种新方法。